On the basis of the Kaplan–Meier survival estimates, the group of patients who had tumours with TMPRSS2:ERG gene fusion had a much greater rate of recurrence at 5 years (58.4%) than patients who lacked the fusion gene (8.1%; P<0.0001) (Figure 2). The gene discussed is ERG; the disease is neoplasm.